For example, the combination of allosteric inhibitor ABL001 and classical tyrosine kinase inhibitors (TKIs) targeting BCR-ABL, including imatinib, nilotinib, and dasatinib, in the treatment of chronic myeloid leukemia (CML) yielded a durable and complete regression of the malignancy, as well as tackled the recalcitrant problem of drug-resistance [19]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.